This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2008 Jun 5;358(23):2503-5.

doi: 10.1056/NEJMe0803375.

Aliskiren and dual therapy in type 2 diabetes mellitus

Julie R Ingelfinger

PMID: 18525047
DOI: 10.1056/NEJMe0803375

Editorial

Aliskiren and dual therapy in type 2 diabetes mellitus

Julie R Ingelfinger. N Engl J Med. 2008.

. 2008 Jun 5;358(23):2503-5.

doi: 10.1056/NEJMe0803375.

Author

Julie R Ingelfinger

PMID: 18525047
DOI: 10.1056/NEJMe0803375

No abstract available

PubMed Disclaimer

Comment on

Aliskiren combined with losartan in type 2 diabetes and nephropathy.
Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Parving HH, et al. N Engl J Med. 2008 Jun 5;358(23):2433-46. doi: 10.1056/NEJMoa0708379. N Engl J Med. 2008. PMID: 18525041 Clinical Trial.

Similar articles

Aliskiren combined with losartan in diabetes and nephropathy.
Lindner T. Lindner T. N Engl J Med. 2008 Sep 4;359(10):1068-9; author reply 1069-70. N Engl J Med. 2008. PMID: 18777612 No abstract available.
Aliskiren combined with losartan in diabetes and nephropathy.
Anderson S, Komers R. Anderson S, et al. N Engl J Med. 2008 Sep 4;359(10):1069; author reply 1069-70. N Engl J Med. 2008. PMID: 18777613 No abstract available.
[Renin inhibition and the kidney].
Ecder T. Ecder T. Turk Kardiyol Dern Ars. 2009 Oct;37 Suppl 7:28-31. Turk Kardiyol Dern Ars. 2009. PMID: 20019474 Turkish.
Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
Dalla Vestra M, Simioni N, Masiero A. Dalla Vestra M, et al. Minerva Endocrinol. 2009 Dec;34(4):333-8. Minerva Endocrinol. 2009. PMID: 20046162 Review.
[Advantages and limitations of renin inhibition with aliskiren].
Azizi M, Frank M, Steichen O, Blanchard A. Azizi M, et al. Ann Pharm Fr. 2011 May;69(3):142-50. doi: 10.1016/j.pharma.2011.02.002. Epub 2011 Apr 21. Ann Pharm Fr. 2011. PMID: 21570538 Review. French.

See all similar articles

Cited by

Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors.
DeFronzo RA, Reeves WB, Awad AS. DeFronzo RA, et al. Nat Rev Nephrol. 2021 May;17(5):319-334. doi: 10.1038/s41581-021-00393-8. Epub 2021 Feb 5. Nat Rev Nephrol. 2021. PMID: 33547417 Review.
Renal and cerebral RAS interaction contributes to diabetic kidney disease.
Liu Y, Li L, Qiu M, Tan L, Zhang M, Li J, Zhu H, Jiang S, Su X, Li A. Liu Y, et al. Am J Transl Res. 2019 May 15;11(5):2925-2939. eCollection 2019. Am J Transl Res. 2019. PMID: 31217864 Free PMC article.
THE IMPACT OF CARDIOVASCULAR DRUGS ON GLYCEMIC CONTROL: A REVIEW.
Grodzinsky A, Arnold SV, Jacob D, Draznin B, Kosiborod M. Grodzinsky A, et al. Endocr Pract. 2017 Mar;23(3):363-371. doi: 10.4158/EP161309.RA. Epub 2016 Dec 14. Endocr Pract. 2017. PMID: 27967225 Free PMC article. Review.
Management of Diabetic Nephropathy in the Elderly: Special Considerations.
Abdel-Rahman EM, Alhamad T, Reeves WB, Awad AS. Abdel-Rahman EM, et al. J Nephrol Ther. 2012 Oct;2(5):124. J Nephrol Ther. 2012. PMID: 24010011 Free PMC article.
The effect of direct renin inhibition alone and in combination with ACE inhibition on endothelial function, arterial stiffness, and renal function in type 1 diabetes.
Cherney DZ, Scholey JW, Jiang S, Har R, Lai V, Sochett EB, Reich HN. Cherney DZ, et al. Diabetes Care. 2012 Nov;35(11):2324-30. doi: 10.2337/dc12-0773. Epub 2012 Jul 26. Diabetes Care. 2012. PMID: 22837362 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information